tiprankstipranks
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market
IPHA
Innate Pharma
RESEARCH TOOLSreports

Innate Pharma (IPHA) Income Statement

132 Followers

Innate Pharma Income Statement

Last quarter (Q4 2025), Innate Pharma's total revenue was €-2.07M, a decrease of -112.52% from the same quarter last year. In Q4, Innate Pharma's net income was €-27.63M. See Innate Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
€ 2.79M€ 12.62M€ 51.90M€ 57.67M€ 12.11M
Gross Profit
€ 2.79M€ 12.62M€ 5.62M€ 6.01M€ -22.30M
Operating Expenses
€ 56.21M€ 64.20M€ 18.29M€ 63.44M€ 25.52M
Depreciation and Amortization
€ 5.09M€ 1.99M€ 5.09M€ 45.41M€ 4.60M
EBITDA
€ -43.65M€ -46.91M€ -1.84M€ -12.28M€ -43.23M
Operating Income
€ -53.42M€ -51.58M€ -12.67M€ -57.42M€ -47.83M
Other Income/Expenses
€ 4.25M€ 2.10M€ 5.10M€ -547.00K€ 2.35M
Pretax Income
€ -49.18M€ -49.47M€ -7.57M€ -57.97M€ -45.48M
Net Income
€ -47.24M€ -49.47M€ -7.57M€ -58.10M€ -52.81M
Per Share Metrics
Basic EPS
€ -0.53€ -0.61€ -0.09€ -0.73€ -0.57
Diluted EPS
€ -0.53€ -0.61€ -0.09€ -0.73€ -0.57
Weighted Average Shares Outstanding
 89.42M 81.05M 84.11M 79.59M 79.54M
Weighted Average Shares Outstanding (Diluted)
 89.42M 81.05M 84.11M 79.64M 79.54M
Currency in EUR

Innate Pharma Earnings and Revenue History